Our second Modulating the Tumour Microenvironment conference presents innovations for enhancing the immune anti-tumour response and overcoming inhibitory factors. It is becoming clear that many immunosuppressive mechanisms are at work. The checkpoint inhibitors are not living up to expectations, and for these and other antagonists to be effective, it is necessary to control Tregs and manipulate myeloid-derived and other suppressor cells in the tumour microenvironment (TME). The leaders in the field are also paying attention to the role of cytokines and the importance of Fc-engagement for effective targeting.  


Coverage will include, but is not limited to:


  • Novel approaches to target the tumour stroma
  • Targeting immune checkpoint inhibitors (CPIs) and antagonists (eg PD-1, CTLA-4): overcoming limitations
  • Targeting regulatory T cells (Tregs) to manipulate the tumour vasculature and enhance T-cell tumour targeting
  • Targeting myeloid-derived and other suppressor cells to overcome inhibitory mechanisms
  • Focus on Fc engagement for effective targeting: Fc-optimization of immuno-modulatory antibodies; targeting antibody checkpoints FcγRIIb
  • Bispecific agonists with checkpoint blockade
  • Measures to enhance efficacy of agonistic immuno-stimulatory antibodies
  • Design of therapeutics to ensure activity in the TME and not in the periphery
  • Innovative approaches with cytokines: mechanisms of action and benefits; impact of the cytokine environment on the immuno-suppressive cell populations infiltrating tumours
  • Focus on isotype selection: IgA, IgG1, IgG2
  • Impact of oncolytic viruses and vector vaccines on immune modulation
  • Targeting cancer-specific glycoforms and glyco-immune checkpoints

If you would like to submit a proposal to give a presentation at this meeting, please CLICK HERE.


The deadline for priority consideration is 26 April 2019.


All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

Nicole Lyscom PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+44) 7791 866489
Email: nlyscom@healthtech.com


For partnering and sponsorship information, please contact:

Companies A-K
Jason Gerardi
Senior Manager, Business Development

Cambridge Healthtech Institute
Phone: (+1) 781.972.5452
Email: jgerardi@healthtech.com


Companies L-Z
Ashley Parsons
Manager, Business Development

Cambridge Healthtech Institute
Phone: (+1) 781.972.1340
Email: ashleyparsons@healthtech.com